Fannie Mae, Freddie Mac shares tumble after conservatorship comments
SAN RAFAEL, Calif. - BioMarin Pharmaceutical (TADAWUL:2070) Inc. (NASDAQ:BMRN) reported better-than-expected fourth quarter results and provided an optimistic forecast for 2025, sending its shares up 5% in after-hours trading on Wednesday.
The biotechnology company posted adjusted earnings per share of $0.92 for Q4, significantly beating the analyst consensus of $0.55. Revenue came in at $747 million, surpassing estimates of $711.42 million and representing a 16% increase YoY.
BioMarin’s strong performance was driven by robust demand for its rare disease treatments, particularly VOXZOGO for achondroplasia. VOXZOGO sales surged 42% YoY to $208 million in Q4.
"Our operational transformation and strong financial execution in 2024 is the first step in BioMarin’s ambitious multiyear growth plan," said Alexander Hardy, President and CEO of BioMarin.
Looking ahead, the company provided an upbeat outlook for 2025. BioMarin expects full-year revenue between $3.1 billion and $3.2 billion, compared to the consensus estimate of $3.1 billion. Adjusted earnings per share are projected to be $4.20-$4.40, above analysts’ expectations of $4.16.
The positive guidance reflects BioMarin’s confidence in continued growth of VOXZOGO globally and solid demand across its enzyme therapies portfolio. The company also anticipates advancing several pipeline candidates in 2025, including potential treatments for Duchenne muscular dystrophy and multiple skeletal conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.